focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Rule 2.9 Announcement

2 Nov 2018 12:36

RNS Number : 2122G
Sinclair Pharma PLC
02 November 2018
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

2 November 2018

Sinclair Pharma plc

("Sinclair" or the "Company")

Rule 2.9 Announcement

 

In accordance with Rule 2.9 of the City Code on Takeovers and Mergers, the Company confirms that, as at 08:00 am on 2 November 2018, it had 517,657,084 ordinary shares of 1 pence each in issue and admitted to trading on AIM. No ordinary shares are held in treasury. Accordingly, the total number of voting rights in Sinclair is 517,657,084. The International Securities Identification Number ("ISIN") for Sinclair's ordinary shares is GB0033856740.

 

For further information, please contact:

Sinclair Pharma plc 

+44 (0) 20 7467 6920

Chris Spooner

Alan Olby

Andy Crane

Rothschild (Lead Financial Adviser to Sinclair)

+44 (0) 20 7280 5000

Dominic Hollamby

Julian Hudson

Josh Johnson

 

 

Peel Hunt LLP (Joint Financial Adviser, NOMAD and Joint Broker to Sinclair)

 

 

+44 (0)20 7418 8900

James Steel

Michael Nicholson

Oliver Jackson

FTI Consulting (Public Relations Adviser to Sinclair)

+ 44 (0) 203 727 1000

Ben Atwell

Brett Pollard

Stephanie Cuthbert

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RTTBTBTTMBJMBIP

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.